Alogliptin benzoate 850649-62-6

99% up by HPLC, PMDA/DMF

Product categories

New Products

Product Details

Product name	Alogliptin benzoate
CAS No.	850649-62-6
Molecular Formula	C18H21N5O2.C7H6O2
Molecular Weight	461.52
Quality Standard	98% up by HPLC
Appearance	White powder

COA of Alogliptin benzoate

ITEMS	SPECIFICATION	RESULT
Appearance	White or off-white crystalline powder	Complies
Melting point	181.0°C ~185.0°C	182-184°C, melting and decomposition
Specific rotation	+13° ~ +18°	+14.6°
Identification	1. UV: maximum absorption at the wavelength of 278+2nm	Complies
	2. IR: be consistent with standard	Complies
	3. HPLC： the retention time of the main peak of the solution should be consistent with the retention time of the main peak of the reference solution.	Complies
Water	≤ 0.5%	0.15%
Residue on ignition	≤ 0.2%	0.09%
Heavy metals	≤ 20 ppm	Complies
Enantiomer	≤ 0.5%	ND
Residual solvents	Ethanol ≤ 5000ppm	985 ppm
	DMF ≤ 880 ppm	ND
	DCM ≤ 600 ppm	ND
	TOL ≤ 890 ppm	ND
	IPA ≤ 5000 ppm	ND
Related substances	Single impurity ≤ 0.1%	0.01%
Related substances	Total impurities≤ 2.0%	0.05%
Assay	98.0% - 102.0%	100.01%
Conclusion	The sample complies with the above specification

Usage

Alogliptin benzoate is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4). Eating stimulates the small intestine to secrete elevated concentrations of incretins, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), into the bloodstream. These hormones cause islet beta cells to release insulin in a glucose-dependent manner, but these hormones are inactivated by the DPP-4 enzyme within minutes. Inhibition of DPP-4 activity by alogliptin slows the inactivation of these incretins, thereby increasing blood concentrations of these hormones and reducing fasting and postprandial blood glucose in a glucose-dependent manner in patients with type II diabetes.

*Products under the patent are only for R&D use